Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.800
+0.040 (2.27%)
Mar 5, 2026, 10:55 AM EST - Market open
Coherus Oncology Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Coherus Oncology stock have an average target of 5.51, with a low estimate of 1.05 and a high estimate of 10. The average target predicts an increase of 206.11% from the current stock price of 1.80.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 22, 2026.
Analyst Ratings
The average analyst rating for Coherus Oncology stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Initiates $10 | Buy | Initiates | $10 | +455.56% | Jan 22, 2026 |
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $4 | Hold → Strong Buy | Upgrades | $4 | +122.22% | Sep 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +288.89% | Apr 29, 2025 |
| UBS | UBS | Hold Maintains $1.5 → $1.05 | Hold | Maintains | $1.5 → $1.05 | -41.67% | Apr 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +288.89% | Mar 11, 2025 |
Financial Forecast
Revenue This Year
44.29M
from 266.96M
Decreased by -83.41%
Revenue Next Year
79.57M
from 44.29M
Increased by 79.63%
EPS This Year
-1.47
from 0.25
EPS Next Year
-0.98
from -1.47
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 49.3M | 102.1M | ||||
| Avg | 44.3M | 79.6M | ||||
| Low | 41.2M | 60.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -81.5% | 130.4% | ||||
| Avg | -83.4% | 79.6% | ||||
| Low | -84.6% | 37.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.40 | -0.53 | ||||
| Avg | -1.47 | -0.98 | ||||
| Low | -1.50 | -1.36 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.